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Abstract: The number of cancer survivors is increasing as a consequence of improved therapeutic
options. Many families are suffering from the resultant financial burden. Our study aims to determine
the total medical cost for 5 years after the initial diagnosis of childhood cancers. A customized dataset
from the Korean National Health Insurance Claims Database was requested for this study. A total of
7317 patients were selected to determine the total medical cost. The costs are presented as the 2%
trimmed mean value to exclude extreme costs. The medical costs were further classified according to
cancer type, treatment phase, and socioeconomic status. Multiple linear regression analyses were
performed. The average total medical cost per patient is 36.8 million Korean Wons or 32,157 United
States Dollars. Analysis of socioeconomic status revealed that the higher income group demonstrated
higher medical expenditure when compared to other groups. Analysis of the treatment phase showed
that costs associated with the early phase of treatment are the highest, especially in the first 3 months
after initial diagnosis. To alleviate the financial burden and reduce the socioeconomic disparities
associated with medical care and costs, a better understanding of the current experience of patients
and their families is required.
Keywords: childhood cancer; medical cost; socioeconomic status; financial burden; national health
insurance; Korea
1. Introduction
Cancer is the second leading cause of death globally. According to a World Health Organization
report, cancer resulted in 9.6 million deaths in 2018 [1]. In addition, cancers are a leading cause
of death in children and adolescents and their prevalence has been increasing since globally [2–5].
In high-income countries, cancer is the number one cause of disease-related death [2,6].
Although deaths from childhood cancers are still high, childhood cancer is curable with advanced
medical therapy and technology. Several years of research have improved treatment options for cancer
patients, thus improving their survival rate [7,8]. In the United States, the 5-year survival rate for
childhood cancer in 2020 is 84%, whereas it was 58% in the mid-1970s and 79% in the mid-1990s [9].
In the United Kingdom, the 5-year survival rate in 2020 is between 76% and 82%, whereas it was 36%
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in 1970 [10]. Also, South Korea (Korea) shows improvement in the 5-year survival rate improving from
52% in the 1980s to over 80% by 2020 [11–13].
Along with the increased number of childhood cancer cases and survivors, the cost of these
treatments and the financial burden on patients and their families are high [14–18]. The cost of
childhood cancer treatment is also high in the United States and begins at 833,000 United States
Dollars (USD) [16]. The medical expense associated with childhood cancer treatment and care has also
increased to 87.7 billion Korean Wons (KRW) in 2014 from KRW 83.1 billion in 2010 [5].
For childhood cancer patients, the financial burden on their family is higher than that associated
with treatment for adult cancer patients [17,19–21]. A study by Merrill et al. reported that the
average cost per day for childhood cancer treatments was 700 USD higher than that of adult cancer
treatments [22]. Additionally, the hospitalization cost for leukemia patients was higher in children at
55,700 USD compared with adults at 40,200 USD [23].
Families of childhood cancer patients often experience disruptions in the regular employment
of the caregiver, which significantly diminishes the household income [24–26]. Some studies show
that families with childhood cancer patients are driven below the poverty line due to high medical
costs [24,26–28]. Furthermore, some patients and their families make treatment decisions based on the
associated cost, which can lead to undesirable outcomes [28,29]. Therefore, it is important to prioritize
and allocate the limited healthcare resources in an efficient manner and provide financial support to
patients and their families.
Understanding the economic impact of childhood cancer is essential. There are very few
studies describing the financial burden associated with medical treatments and its impact on patients’
families [22,24]. The purpose of this study is to investigate the burden of childhood cancer costs on
cancer survivors and their families based on socioeconomic status. To this end, we examined the
medical costs associated with cancer survival for 5 years after the initial cancer diagnosis, based on
childhood cancer type and socioeconomic status.
2. Materials and Methods
2.1. Data
The National Health Insurance Service (NHIS) database includes medical diagnoses, treatments,
drug information, hospital information, and demographic information. Medical diagnoses are indicated
using International Statistical Classification of Diseases and Related Health Problems, 10th revision
(ICD-10) codes. For this study, we requested a customized dataset of children who were diagnosed
with cancer (C00-C99) and their parents’ income data from 2002 to 2015 from the Korean National
Health Insurance Claims Database.
2.2. National Health Insurance in Korea
Korea has a Universal Health Insurance system that has a single insurer, NHIS. The compulsory
premium is deducted based on the individual’s income. However, there is no difference in receiving
healthcare services. National Health Insurance (NHI) has two sections, which are covered services and
non-covered services. The NHI has 65% of covered medical service items and 35% of non-covered
items for medical services. Those items in non-covered services are usually non-essential services and
expensive items.
In general, the out-of-pocket (OOP) money for inpatient care services in covered items is 20%,
while outpatient care services in the covered items are 30–50%. The OOP for non-covered items services
is 100%. From the day of diagnosis, the cancer patient’s OOP for inpatient care and outpatient care
services reduces to 5% for 5 years. Therefore, in this study, OOP for patients was 5% of the medical cost.
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2.3. Study Population
From a total of 21,205 patients aged 0–17 who were diagnosed with cancer, we applied a 1-year
washout period to identify and include newly diagnosed cancer patients for the study. To obtain
socioeconomic status, we extrapolated insurance payment data from the patient’s parent income data
and linked the two parameters together. We excluded 5598 patients who lacked parent data. Our study
design also excluded cancer patients that died within 5 years of diagnosis. Finally, we excluded
150 patients whose medical expenditure was in the upper and lower 1% of all medical costs. A total of
7317 patients were ultimately used for the study.
2.4. Medical Cost
Medical costs in our study were obtained from NHI claim data, which are the real costs of medical
services. Thus, we are presenting the insurer’s perspective as average costs (mean values). To eliminate
the extreme values, we applied a 2% trimmed mean and excluded the upper and lower 1% values.
The cost includes all medical treatment expenses for 5 years after the initial diagnosis. For costs
between the years 2003 to 2014, we applied an adjustment in the unit price per score to reflect the actual
value of the cost in the year 2015. The medical costs were corrected by multiplying the unit price by the
following adjustment rates: 1.30 (2003), 1.26 (2004), 1.23 (2005), 1.19 (2006), 1.15 (2007), 1.13 (2008), 1.10
(2009), 1.09 (2010), 1.08 (2011), 1.06 (2012), 1.04 (2013), and 1.02 (2014). In this study, all amounts are
presented in KRW [1 USD is approximately equivalent to 1144.40 KRW on average for the year 2015].
2.5. Cancer Types
In our study, we grouped childhood cancers into six categories based on the International
Classification of Childhood Cancer [30] and Korean Central Cancer Registry Annual Report [31]:
leukemia (C91-C95), brain and central nervous system cancer (C70-C72), non-Hodgkin’s lymphoma
(C82-C85, C96), bone and articular cartilage cancer (C40-C41), mesothelioma soft tissues (C45-C49), and
the remaining group of ‘other’ cancers. We classified cancer treatment into three phases: early, middle,
and late phases. The early phase is the first year following diagnosis, the middle phase includes the
second to the fourth year following diagnosis, and the late phase is the fifth year following diagnosis.
The early phase has been further divided into 3, 6, 9, and 12 months.
2.6. Socioeconomic Status
Socioeconomic status is classified based on the parents’ health insurance premium, which is
reflective of the household income. The status is categorized into the following quartile ranges: low
(KRW 0−43,260,000), mid-low (KRW 43,261,000−74,555,000), mid-high (KRW 75,556,000−122,370,000),
and high (KRW 122,371,000 or more).
2.7. Statistical Analysis
The main analysis was performed using multivariable linear regression. The analysis was
performed to determine the association between the outcome variable, cost of cancer treatments,
and covariates. For sub-group analysis, we performed multivariable linear regressions based on the
patients’ socioeconomic status. All analyses were performed using the SAS software, version 9.4
(SAS Institute, Cary, NC, USA).
3. Results
3.1. General Characteristics of Study Population
Table 1 shows the general characteristics of the study population. In our study, we included 7317
patients, of whom 27.8% were leukemia patients, 15.2% were brain and central nervous system cancer
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patients, 9.2% were non-Hodgkin’s lymphoma patients, 7.0% were bone and articular cartilage cancer
patients, 5.1% were mesothelioma soft tissue cancer patients, and 35.8% were ‘other’ cancer patients.



















Tertiary hospital 7258 99.2
Other 59 0.8
Hospital region
Capital Area 4656 63.6
Metropolitan Area 820 11.2












Brain and central nervous system cancer 1111 15.2
Non-Hodgkin lymphoma 672 9.2
Bone and articular cartilage cancer 511 7.0
Soft tissues 372 5.1
Other cancers 2620 35.8
3.2. Average Medical Cost of Childhood Cancer Survivors for 5 Years from the Diagnosis
Table 2 displays the average medical cost incurred by childhood cancer survivors from the time of
initial diagnosis until the end of the next 5 years. The total medical cost per patient is 36.8 million
KRW (Approx. USD 32,157). Inpatient services cost 28.3 million KRW (Approx. USD 24,729), whereas
outpatient services cost 8 million KRW (Approx. USD 6991). When classified by cancer type, leukemia
was associated with the highest cost at 53.5 million KRW (Approx. USD 46,749) followed by bone and
articular cartilage cancer at 52.0 million KRW (Approx. USD 45,439) (Supplementary Table S1).
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Table 2. Total medical cost of childhood cancer survivors from the initial diagnosis (mean ± S.D.).
Variable
Total Medical Cost †
Mean ± S.D
Total 36,799 ± 37,485
Sex
Male 39,350 ± 38,670
Female 33,795 ± 36,073
Age at diagnosis
0–4 36,583 ± 35,594
5–9 40,334 ± 38,287
10–14 39,123 ± 39,301
15–17 30,399 ± 36,645
Household income
level
Low 33,081 ± 36,202
Mid-low 35,701 ± 36,582
Mid-high 38,996 ± 38,479
High 42,421 ± 39,720
Treated hospital type
Tertiary hospital 37,071 ± 37,642
Other 5354 ± 9388
Hospital region
Capital Area 39,412 ± 37,858
Metropolitan Area 31,780 ± 37,755
Rural Area 32,490 ± 36,273
Chemotherapy
Yes 50,805 ± 37,890
No 8418 ± 12,934
Radiotherapy
Yes 52,635 ± 42,948
No 31,301 ± 33,867
Surgery
Yes 41,309 ± 42,003
No 31,660 ± 31,041
Medical service
Inpatient 28,321 ± 23,717
Outpatient 8494 ± 7180
† Presented in KRW (Approx. KRW 1140.40 = USD 1.00, on average year 2015). Unit: 1000 KRW.
3.3. Regression Analysis on Childhood Cancer Survivors’ Medical Cost and Usage
Results of a regression analysis on total medical costs for childhood cancer survivors are presented
in Table 3. Relative to patients in high household income, low household income (β: 5,503,525, p-value:
<0.001), mid-low household income (β: 4,358,768, p-value: <0.001), and mid-high household income
(β: 2,099,218, p-value: 0.050) groups had less. Patients undergoing chemotherapy, radiotherapy, and
surgery bore higher medical costs compared with those who did not receive those major treatments
(chemotherapy: β: 22,343,241, p-value: <0.001; radiotherapy: β: 17,198,259, p-value: <0.001; surgery: β:
19,107,892, p-value: <0.001). Patients who went to hospitals in the capital region (β: 1,224,772, p-value:
0.128) and metropolitan area (β: 1,332,197, p-value: 0.269) cost higher compared to rural area hospitals,
yet the difference is not statistically significant. When analyzed according to socioeconomic status,
the medical cost was greater in patients of higher socioeconomic status. This result was unaffected by
cancer type (Supplementary Table S2).
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Table 3. Result of regression analysis on the total medical costs to childhood cancer survivors.
Variable
Total Medical Cost †
β S.E p-Value
Sex
Male 2,279,363 679,966 0.001
Female Ref.
Age at diagnosis
0–4 3,220,951 1,014,015 0.002
5–9 2,073,293 1,075,761 0.054
10–14 3,566,651 984,064 <0.001
15–17 Ref.
Household income level
Low −5,503,525 1,036,325 <0.001
Mid-low −4,358,768 1,041,386 <0.001
Mid-high −2,099,218 1,069,302 0.050
High Ref.
Treated hospital type
Tertiary hospital −4,952,756 3,788,808 0.191
Other Ref.
Hospital region
Capital Area 1,224,772 805,016 0.128
Metropolitan Area 1,332,197 1,204,805 0.269
Rural Area Ref.
Chemotherapy
Yes 33,343,241 812,130 <0.001
No Ref.
Radiotherapy
Yes 17,198,259 827,924 <0.001
No Ref.
Surgery
Yes 19,107,892 791,327 <0.001
No Ref.
Cancer type
Leukemia 29,550,083 1,025,331 <0.001
Brain and central nervous
system cancer 11,842,109 1,063,896 <0.001
Non-Hodgkin lymphoma 11,803,352 1,304,556 <0.001
Bone and articular cartilage
cancer 23,050,088 1,441,362 <0.001
Mesothelioma Soft tissues 7,583,751 1,589,286 <0.001
Other cancers Ref.
† Presented in KRW (Approx. KRW 1140.40 = USD 1.00, on average year 2015).
To investigate the duration of services received, regression analyses on the number of days of
medical service use was performed (Table 4). Leukemia patients used medical services for a longer
duration (104.0 days) compared to any other childhood cancer patients in both inpatient (67.4 days)
and outpatient (36.6 days) service categories.
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Table 4. Result of regression analysis on the duration of medical service (days).
Variable
Total Inpatient Service Outpatient Service
β S.E p-Value β S.E p-Value β S.E p-Value
Sex
Male 5.8 3.0 0.054 4.6 2.1 0.027 1.2 1.7 0.494
Female Ref. Ref. Ref.
Age at diagnosis
0–4 51.4 4.5 <0.001 26.8 3.1 <0.001 24.6 2.6 <0.001
5–9 34.5 4.7 <0.001 14.2 3.3 <0.001 20.2 2.8 <0.001
10–14 25.6 4.3 <0.001 13.3 3.0 <0.001 12.3 2.5 <0.001
15–17 Ref. Ref. Ref.
Household income level
Low −22.7 4.6 <0.001 −4.7 3.1 0.131 −17.9 2.7 <0.001
Mid-low −17.0 4.6 <0.001 −3.2 3.2 0.303 −13.7 2.7 <0.001
Mid-high −6.4 4.7 0.173 −1.6 3.2 0.623 −4.8 2.7 0.081
High Ref. Ref. Ref.
Treated hospital type
Tertiary hospital −11.0 16.6 0.507 1.7 11.5 0.881 −12.8 9.7 0.190
Other ref. ref. ref.
Hospital region
Capital Area −8.2 3.5 0.021 −27.3 2.4 <0.001 19.1 2.1 <0.001
Metropolitan Area −0.1 5.3 0.989 −5.0 3.6 0.173 4.9 3.1 0.114
Rural Area Ref. Ref. Ref.
Chemotherapy
Yes 164.0 3.6 <0.001 91.9 2.5 <0.001 72.0 2.1 <0.001
No Ref. Ref. Ref.
Radiotherapy
Yes 80.7 3.6 <0.001 37.8 2.5 <0.001 42.9 2.1 <0.001
No Ref. Ref. Ref.
Surgery
Yes 48.5 3.5 <0.001 34.5 2.4 <0.001 14.0 2.0 <0.001
No Ref. Ref. Ref.
Cancer type
Leukemia 104.0 4.5 <0.001 67.4 3.1 <0.001 36.6 2.6 <0.001
Brain and CNS cancer 61.4 4.7 <0.001 25.3 3.2 <0.001 36.1 2.7 <0.001
Non-Hodgkin lymphoma 35.9 5.7 <0.001 25.5 3.9 <0.001 10.4 3.4 0.002
Bone & articular cartilage 101.0 6.3 <0.001 83.4 4.4 <0.001 17.6 3.7 <0.001
Mesothelioma Soft tissues 40.0 7.0 <0.001 21.5 4.8 <0.001 18.4 4.1 <0.001
Other cancers Ref. Ref. Ref.
Int. J. Environ. Res. Public Health 2020, 17, 6020 8 of 13
3.4. Cumulative Medical Cost for 5 Years by Socioeconomic Status
Figure 1 demonstrates the medical costs borne by childhood cancer survivors, based on their
socioeconomic status, in each treatment phase and the cumulative medical cost. Medical costs for
patients were high in the early phase of treatment. When analyzed according to socioeconomic status,
increased medical costs were observed in the first 3 months following diagnosis for the high status
category. The medical costs based on socioeconomic status are as follows: low household income group
at 11.7 million KRW (USD 9776); mid-low at 12.1 million KRW (USD 10,116); mid-high at 12.2 million
KRW (USD 11,083); and high at 15.0 million KRW (USD 12,508) for the first 3 months of the treatment
phase (Supplementary Table S3).
Int. J. Environ. Res. Public Health 2020, 17, x 9 of 14 
 
3.4. Cumulative Medical Cost for 5 Years by Socioecono ic Status 
Figure 1 demonstrates the medic l   y childho d cancer survi ors, based on their 
socioeconomic status, in each treat e t    ulative medical cost. Medical costs for 
patients w re high in the early phase  t. hen analyzed according to socioecon mic status, 
increased medical costs were observe  i  t  fi t  ths following diagnosi  for the high status 
category. The medical costs based on socioeconomic status are as follows: low household income 
group at 11.7 million KRW (USD 9776); mid-low at 12.1 million KRW (USD 10,116); mid-high at 12.2 
million KRW (USD 11,083); and high at 15.0 million KRW (USD 12,508) for the first 3 months of the 
treatment phase (Supplementary Table S3).  
 
  
Figure 1. Medical costs of childhood cancer survivor by socioeconomic status in each treatment phase 
cost and cumulative cost †. † Presented in KRW (Approx. KRW 1140.40 = USD 1 on average, year 2015). 
4. Discussion 
Our study focused on the medical treatment-associated financial burden borne by childhood 
cancer patients and their families based on their socioeconomic status. Childhood cancer impacts not 
only the patient, but also the family [17,18,21,32]. In our study, we found that medical expenditure 
varied based on socioeconomic status and treatment phase in Korea. Previous studies on the financial 
burden of childhood cancers were limited to specific hospitals or areas with small sample sizes. 
Because our study utilized NHIS data, which is the real data of the medical cost, our sample size is 
greater and more representative of the Korean population compared to previous studies.  
We found that the medical expenditure at early phases of treatment is the highest. Clinical 
research has reported that during the early phases of cancer treatment, intensive care, lengthy 
hospitalization, and frequent outpatient services are needed. Therefore, after cancer diagnosis, 
patients and their families experience financial stress in addition to the psychological stress 
associated with the diagnosis itself [14,17,25,27]. Similar to our results, Warner et al. reported that in 
the first year of diagnosis, childhood cancer patients and families are financially vulnerable [28]. 
Considering that the main caregiver for the patient is a parent, the inevitable disruption of parents’ 
employment in many cases increases the financial burden on the family [15,21,27,32]. Although this 
financial burden affects families independently of socioeconomic status, patients and their families 
in the low status category suffer more [27,28,33–36]. 
Cancer treatment requires long-term care that can place an immense financial burden on 
patients’ families [37,38]. Some patients could make treatment decisions based on costs [19,34–36,39]. 
Figure 1. Medical costs of childhood cancer survivor by socioeconomic status in each treatment phase
cost and cumulative cost †. † Presented in KRW (Approx. KRW 1140.40 = USD 1 on average, year 2015).
4. Discussion
Our study focused on the medical treatment-associated financial burden borne by childhood
cancer patients and their families based on their socioeconomic status. Childhood cancer impacts not
only the patient, but also the family [17,18,21,32]. In our study, we found that medical expenditure
varied based on socioeconomic status and treatment phase in Korea. Previous studies on the financial
burden of childhood cancers were limited to specific hospitals or areas with small sample sizes. Because
our study utilized NHIS data, which is the real data of the medical cost, our sample size is greater and
more representative of the Korean population compared to previous studies.
We found that the medical exp nditure at arly phases of treatm nt is the hig st. Clinical rese rch
has r ported that during t e early phas s of cancer treatme t, intensive care, l gthy hospitalization,
and frequent utpatient services are n eded. Therefore, after cancer diagnosis, patients a d their
famili s experienc financ al tr ss in additio to the psychological stress associated with the diagnosis
itself [14,17,25,27]. Similar to our results, Warner et l. report d that in the first y ar of diagnosis,
childhood cancer patients and families are financially vulnerable [28]. Considering that the main
caregiver for the patient is a parent, the inevitable disruption of parents’ employment in many cases
increases the financial burden on the family [15,21,27,32]. Although this financial burden affects
families independently of socioeconomic status, patients and their families in the low status category
suffer more [27,28,33–36].
Cancer treatment requires long-term care that can place an immense financial burden on patients’
families [37,38]. Some patients could make treatment decisions based on costs [19,34–36,39]. To reduce
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this financial burden, governments and organizations have developed programs to aid patient’s and
family’s financial burden. For example, the Korean government has a special system in place wherein
a cancer patient pays only 5% of the total OOP costs covered for 5 years after the diagnosis [37,40].
The United States has government support care programs, local support networks, and pharmaceutical
assistant programs to financially assist financially [41]. Also, the United Kingdom have government
grants and charity grants for cancer patients [42]. While this system provides some relief to patients
and families, the treatments are expensive, and some facets of treatment are not covered by the national
health insurance. As our results demonstrate, the medical cost for childhood cancer survivors varies
based on socioeconomic status. Importantly, the results only include treatments covered by insurance.
In addition to the special system described above, the government also provides financial support
to low-income patients who pay health insurance premiums below KRW 100,000 [40]. However,
our study found that the medical costs of the low status group and the mid-low status group showed
not much of a difference on average. The mid-low status group had decreased cumulative medical
costs at 1-year post-diagnosis. Patients did not have different medical accessibility or service based on
their socioeconomic status. However, due to the uncovered items and 20% of OOP cost, patients could
have received different services. Thus, it could cause difference in medical services. Currently, most
supportive programs target patients in low socioeconomic status based on the household income. Yet,
people in the mid-low group have limited support programs towards medical treatment. Therefore,
we suggest expanding financial support for families who are in need.
Studies on the financial burden of cancer patients were conducted for years, yet few studies
on the financial burden of childhood cancer patients and their families were conducted. Childhood
cancer patients require long term follow-up care and support to adjust in society after they spent most
of their time at the hospital [37,38,43,44]. They have higher risks of developing second cancer and
complications [44–47]. All those factors led to expensive medical costs [14,24,28,29,38]. Furthermore,
when cancer is diagnosed, patients start treatment so that they can avoid metastasis and obtain
successful results from the treatment [48–50]. Also, intensive treatments in the early treatment phase
can reduce the recurrence of cancer [48]. Thus, the patient and family often want to start advanced
treatment immediately, despite the higher cost. Often those expensive treatments are ones that the
patient and family suffer from financial burden [50–52]. The overall treatment plan could be affected
due to financial reasons [52,53]. Unfortunately, patients with low socioeconomic status are those who
tend to alter the treatment plan [14,16,33,53].
Although our study population was under a universal health insurance system, there was a
difference among socioeconomic statuses. We believe the reason behind the difference in medical costs
among the socioeconomic status is on the costs of uncovered items. If we factored in non-covered
treatments in our calculations, it would further exacerbate the gap in financial burden based on
socioeconomic status. Cancer treatments are using advanced technology. There are treatments that
private insurance would not cover. Thus, patients face high OOP costs, and difficulty in access to
medical treatments varies depending on their financial capability [19,35,54,55]. For pediatric cancer
patients, long term care in hospitals, and frequent outpatient visits are needed [56,57] that the difference
in doctor’s visit due to socioeconomic level could lead to different outcomes.
The socioeconomic status should not determine the end outcome of the disease. The high medical
costs associated with cancer treatments, governments, and various organizations have established
a financial support program for patients. However, the financial burden on families continues to
remain high [14–17,19,20,28,32,58]. Under the national health insurance system in Korea, the essential
treatment will be given equally to patients regardless of premium. Even with NHI and its covered
items, which are essential services compared to non-covered items, there are differences. The difference
lies in whether patients will use services at the minimum level or use services at an insufficient level.
The use of the intensive care unit is an example. There may be a difference between using the intensive
care unit after surgery for a sufficient period of time with an emphasis on the safety of the patient or
using the intensive care unit for a minimum period of time. The latter would place an emphasis on the
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cost of the care, and the patient would be more quickly transferred to the general ward. We suggest
installing the proper allocation of medical resources and institutional support systems in order to lower
the associated financial burden on the patients and their families [14,19,20,28].
There are some limitations to our study. First, the medical expenses calculated in our study only
indicate those covered by health insurance. We were unable to obtain non-covered medical expenses;
most costs related to childhood cancers are covered by national health insurance based on the Universal
Health Insurance system in Korea. Secondly, we did not include the medical expenses associated with
subsequent non-cancer-related to doctor visits and treatments. As cancer treatments comprise very
intensive care, we expect that other treatment costs would not substantially alter our results. Thirdly,
we only considered whether the patients received treatments such as surgery, chemotherapy, and
radiation, but not the frequency at which they received them. Also, we were not able to distinguish the
stage of cancer and the specific treatment for each cancer type. Fourthly, the number of cancer cases
in our study is less than the actual societal rate. For the study, we included patients who have their
patients’ data so that we can measure their socioeconomic status. Lastly, the medical cost calculated for
our study includes the direct cost only. We were not able to obtain indirect cost from the insurance
claim data. Therefore, further studies are necessary to overcome these limitations.
5. Conclusions
In conclusion, as improved medical treatments increase the numbers of childhood cancer survivors,
the economic burden associated with medical treatment also increases. A better understanding of
how the financial burden is unevenly distributed across socioeconomic classes is required to reduce
the disparities in medical treatment received by patients. In addition, considering the duration of
healthcare needed for patients, establishing a continuous economic support policy would be beneficial
for lowering the financial burden on childhood cancer patients and their families.
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